Methods and techniques

Assessment of ileal function by abdominal counting of the retention of a gamma emitting bile acid analogue

E H THAYSEN,* MARIANNE ORHOLM, T ARNFRED, J CARL, and P RØDBRO

From the Departments of Medical Gastroenterology, Clinical Chemistry, and Clinical Physiology, Aalborg Regional Hospital, Denmark

SUMMARY In eight patients without gastrointestinal complaints and 30 patients with various gastrointestinal disorders ileal bile acid conservation was assessed by oral administration of $^{75}$Se 23-selena-25-homocholic acid (SeHCAT) followed by abdominal gamma counting (SeHCAT-test). The results of the test correlated fairly well with the clinical features and with the [$^{1-14}$C]-cholylglycine breath test including faecal $^{14}$C measurements (breath test). Of the two bile acid absorption tests the new is perhaps the more sensitive and is the one most easily performed.

Bile acid malabsorption is usually the result of terminal ileopathy, but it may also occur in the absence of conventional ileal disease. The latter applies, for example, to diseases associated with excess small gut luminal flow such as secretory, osmotic, and postvagotomy diarrhoea, where the abnormal detergent loss is an epiphenomenon. Furthermore, it also applies to the so-called idiopathic bile acid diarrhoea; this disorder shows no abnormal gastrointestinal signs apart from an unexplained moderate loss of bile acid resulting in cholegenic enteropathy that is promptly and permanently relieved by long-term cholestyramine therapy. In clinical practice, bile acid malabsorption is detected by means of the trihydroxy bile acid absorption tests, which, in fact, represented the most sensitive assays of inflammatory disease of the distal ileum. Counting radioactivity in the stool is inconvenient, and, as suggested by Hofmann, a gamma-labelled bile acid which could be detected by external counting might greatly facilitate the technique.

Recently Amersham International Ltd has produced the taurine conjugate of $^{75}$Se 23-selena-25-homocholic acid (SeHCAT) which is absorbed from the gut and secreted into bile at the same rate as $^{14}$C cholic acid. We have had the opportunity of making a preliminary evaluation of this compound using abdominal gamma counting (SeHCAT-test) to assess bile acid conservation in various disorders. In order to evaluate the results achieved the [$^{1-14}$C]-cholylglycine breath test including $^{14}$C measurement in stool (breath test) was performed simultaneously with the SeHCAT-test.

Methods

Patients
Those studied included 38 patients, 26 women and 12 men, with a mean age of 47 years (22–71 years). Excess bile acid loss was not suspected in eight patients with no history of gastrointestinal disease and in four patients with ulcerative colitis. In six patients with rather extensive resection or inflammation of the distal ileum, bile acid malabsorption was marked, whereas it was suggested in 20 patients with chronic diarrhoea from various causes.

5–9 $\mu$Ci $^{75}$SeHCAT (Amersham, SCQ.3415) and approximately 8 $\mu$Ci (1-$^{14}$C)-glycocholic acid (Amersham, CFA.492) were administered orally with a liquid test meal to the fasting patient. The $^{14}$C breath test, which is in routine use in this department, was performed as described earlier, but special precautions were taken to measure $^{14}$C in stool containing various amounts of this isotope and $^{75}$Se.

In the SeHCAT-test the initial count rate (‘$100\%$
value’) was measured three hours after the intake of isotope (day 0), with the patient lying supine below an uncollimated large field-of-view gamma camera (Ohio Nuclear Sigma 410). The distance from the couch to the gamma camera crystal (diameter 51 cm) was maintained at 44 cm, and the crystal was centred over the middle of the abdomen. The activity of $^{75}$Se was measured in a 20% window around the 265 and 280 keV photon peaks. The background was evaluated for 300 seconds immediately before and after the patient was measured, which was also for 300 seconds. The average background count rate (approximately 200 counts per second) was subtracted from the patient count rate to give the net count rate (cps). After the second examination, which was performed on day 5, the net count rate day 5 was expressed as a percentage of the net count rate at day 0 – that is,

$$\text{% retention} = \frac{\text{net count day 5}}{\text{net count day 0}} \times 100.$$

Typically, the initial count rate for a 8 $\mu$Ci dose under these conditions was 5000 cps, equivalent to approximately 30 000 cps in the entire spectrum. With our gamma camera there was no measurable dead time loss before three times the maximal dose which was used in the patients.

Results

From Table 1 it appears that out of the eight patients without gastrointestinal complaints five only, serving as controls, had negative breath tests. In order to further increase the control material four patients with ulcerative colitis and no evidence of backwash ileitis were also included. On the basis of this sample a day 5 retention of 36% was chosen provisionally as the SeHCAT-test lower limit of normal, whereas values between 30 and 35% were considered borderline. The results of the test in the three patients excluded as controls were, accordingly, interpreted as either positive (13% retention in one) or borderline.

The term ‘chronic diarrhoea’ (Table 1) covered a wide clinical spectrum, as indicated by an asterisk in Table 2. This was reflected in the responses to both tests. On the basis of the limits adopted, the SeHCAT-test was positive in every case of ileopathy and of small gut excess luminal flow. The six cases of idiopathic bile acid diarrhoea (definition given previously) all had positive SeHCAT-tests and chronic watery diarrhoea which was relieved only by cholestyramine. With no malabsorption of fat and carbohydrates the ‘allergic' diarrhoea subsided on total oral fasting and later on cromoglycate (Nalcrom), only to recur whenever this medication was withdrawn. Before treatment the SeHCAT-test was positive, probably reflecting rapid small gut transit. The case of surreptitious lipid overload was caused by a hidden intake of chocolate corresponding to about 250 g triglyceride fat per day (absorptive Tmax some 150 g/day). Under strict dietary control a severe steatorrhoea vanished, and simultaneously the SeHCAT- and breath tests became negative. On the basis of the clinical features the SeHCAT-test seems to be slightly more sensitive and not less specific than the breath test.

The reproducibility of counting $^{75}$Se was evaluated from duplicate determinations where the second measurement took place when the patient had been ambulant for a couple of minutes. On day 0 the coefficient of variation was 1.2-2.4%, on day 5: 1.4%. Furthermore, two subjects were investigated twice (on two different doses of isotope), after an interval of three to six weeks. The day 5 retention percentages were 0 and 0% in one patient, and 43% and 44% in the other.

Finally, it may be mentioned that both isotopes have been measured simultaneously in the stool. The faecal excretion of $^{75}$Se was between 1.7 and 10 times higher than that of $^{14}$C.

Discussion

The use of a gamma camera as an external counter of a region of interest (the abdomen) raises a number of problems. Certain features are desirable – namely, good precision of retention percentage measurements, independence of dead time effects, a low dosage of radiation to the patient, and as little influence as possible of isotope distribution and body build and positioning of the
patient. These requirements are not all attainable and some of them tend, in fact, to be mutually exclusive. The only variables in our investigations were administered isotope dose and the distance between patient and gamma camera; and our procedure must, therefore, be regarded as a reasonable compromise. Our overall results are similar to those obtained by Merrick et al (unpublished observations) who used a clinical whole-body counter. They indicate that it is, indeed, possible to obtain results with an uncollimated gamma camera which are comparable with those found with a clinical whole-body counter. To what degree our results may deviate from those found with more sophisticated instrumentation is to be the subject of further investigation. From experiments on phantoms the worst possible deviations from a well-mixed isotope distribution may be simulated. Such experiments show that it would still be possible to detect patients with bile acid loss, but the technique needs further refinement in borderline cases.

Interpretation of the SeHCAT-test is mainly derived from comparison with the breath test, which is apparently the most sensitive assay of bile acid absorption available to the clinical routine. The two tests are based on different techniques and they have, in fact, been performed simultaneously.

The lower limit of normal adopted for the SeHCAT-test implies borderline results in two and a positive result in one out of the eight patients without gastrointestinal complaints. As the breath test was borderline in these three patients the interpretation of the SeHCAT-test has not been revised so far. It is unfortunate, however, that shortage of SeHCAT prevented re-examination of the patient with the positive test. As regards the 20 patients with chronic diarrhoea the outcome of both tests is often in agreement. Where discrepancies occur, with negative or borderline breath tests and positive SeHCAT-tests, the latter test is apparently the more reliable when judged from the final diagnoses (Table 2). As regards the breath test, measurement of faecal radioactivity is essential for the evaluation of bile acid absorption. In [1-14C]-cholylglycine the label is in the glycine moiety. When not absorbed in the small gut the tracer is exposed to bacterial deconjugation in the colon; there is then release of the absorbable aminoacid which is partly metabolised to 14CO2 and exhaled. In this way faecal radioactivity is the result of a competition between colonic absorption and faecal excretion of 14C. In contrast, the SeHCAT label is in the bile acid analogue and will stay here despite bacterial degradation of the compound. The difference between the two tracers is reflected in the higher faecal excretion of 75Se as compared with 14C as mentioned under ‘Results’, and this again may perhaps explain why the breath test is the less sensitive of the two assays.

Table 2  Results of bile acid absorption tests in relation to disease (n=33)

<table>
<thead>
<tr>
<th>[1-14C]-cholylglycine breath test</th>
<th>75SeHCAT-test</th>
<th>Disease</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative (n=12) Negative (n=10)</td>
<td>Ulcerative colitis/ischaeic colitis (without evidence of ileal damage) 4*</td>
<td>5*</td>
<td></td>
</tr>
<tr>
<td>Positive (n=2)</td>
<td>Alternating diarrhoea and constipation 4*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>Borderline (n=10) Borderline (n=3)</td>
<td>Postgastrectomy 1*</td>
<td>2*</td>
<td></td>
</tr>
<tr>
<td>Positive (n=7)</td>
<td>Idiopathic bile acid diarrhoea 2*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>Positive (n=11) Positive (n=11)</td>
<td>Ileal resection (&lt;5 cm) 1*</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Ileitis</td>
<td>Ileal resection or inflammation 1*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>Idiopathic bile acid diarrhoea 2*</td>
<td>Secretory diarrhoea (apudoma) 1*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>Allergic diarrhoea 1*</td>
<td>Suppurative lipid overload 1*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>Suppurative magnesium abuse 1*</td>
<td>(some 250 g triglyceride fat per day) 1*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>Postgastrectomy 1*</td>
<td>Postgastrectomy dumping 1*</td>
<td>1*</td>
<td></td>
</tr>
</tbody>
</table>

* Denotes chronic diarrhoea in Table 1.
In brief, it is our preliminary experience that the SeHCAT-test competes favourably with the breath test where detection of bile acid malabsorption is concerned. The external counting can be performed with equipment available in most larger hospitals.

We thank Amersham International Ltd for free supply of $^{75}$Se 23-selena-25-homocholic acid. This work was supported by grants to E H Thaysen from the P Carl Pedersen Foundation and the Aalborg Municipal Foundation for Medical Research.

References